The External Scientific Advisory Board (ESAB) evaluates the CTH in all areas of scientific and structural development, including research strategies, appointment of staff, quality control, allocation of BMBF funding, and monitoring of BMBF requirements. The ESAB is particularly involved in all major financial decisions, the set-up of research groups, and investigator-initiated clinical trials. Internal procedures and workflows of the CTH are evaluated annually by the ESAB.
The ESAB consists of elected experts in the field of thrombosis and hemostasis research, cardiovascular diseases, health care, therapy and drug development.
ESAB Meetings, second funding period (2015-2020)
1st Meeting: October 5, 2015
2nd Meeting: October 28, 2016
3rd Meeting: October 19/20, 2017
4th Meeting: November 8, 2018
Speaker of the ESAB
Ingrid Pabinger-Fasching, MD
Position: Professorship for Haemostaseology
Medical University of Vienna, Austria
Chair elect: ISTH Council
Further Information
Deputy Speaker of the ESAB
Klaus T. Preissner , PhD
Position: Spokesman Department of Biochemistry
Faculty of Medicine
Justus-Liebig-University Giessen, Germany
Members of the ESAB
Philip G. De Groot, MD
Position: Professor of Biochemistry of Thrombosis & Hemostasis
Department of Clinical Chemistry & Hematology
University Medical Center, Utrecht, The Netherlands
Further Information
Margitta Elvers, PhD
Position: Head of Molecular Hemostasis
Institute for Hemostasis, Hemotherapy & Transfusion Medicine
University Medical Center Düsseldorf, Germany
Further Information
Meinrad Gawaz, MD
Position: Medical Director
Internal Medicine III – Cardiology & Cardiovascular disease
DHZ – German Heart Center
University Medical Center Tübingen, Germany
Further Information
Bernd Jilma, MD
Position: Associate Professor of Clinical Pharmacology & Internal Medicine
Vice Chair Department of Clinical Pharmacology
Medical University of Vienna, Austria
Further Information
Bettina Kemkes-Matthes, MD
Position: Head of Interdisciplinary Center for Hemostasis
Department of Hematology/Oncology, Angiology & Hemostasis
Medical University of Giessen & Marburg, Germany
Chair: GTH
Further Information
Frank Misselwitz, MD MSc
Position: Head Global Clinical Development Cardiovascular
Bayer Pharma AG, Wuppertal, Germany
Further Information
Stephan Moll, MD
Position: Professor of Medicine
Department of Medicine, Division of Hematology-Oncology
University of North Carolina School of Medicine, Chapel Hill, USA
Further Information
Marc Rodger, MD MSc
Position: Departments of Medicine, Epidemiology & Community Medicine & Obstetrics & Gynecology
Chief and Chair of the Division of Hematology
Ottawa Hospital Research Institute, Ottawa, Canada
Further Information
Joanne van Ryn, PhD
Position: Global Director, Dabigatran Scientific Support
Department CardioMetabolic Disease Research
Boehringer Ingelheim Pharma GmbH & Co KG
Further Information
Former members of the Advisory Board
Roland Derwand, MD, LEUKOCARE AG, Martinsried
Prof. Klaus Dugi, Boehringer Ingelheim GmbH, Ingelheim am Rhein
Prof. Gregory Lip, University of Birmingham, Centre for Cardiovascular Sciences
Prof. Dr. J.W.M. Heemskerk, PhD, Cardiovascular Research Institute, Maastricht
Prof. Stefan Hohnloser, MD, University Hospital Frankfurt, Department Elektrophysiology
Prof. Malte Kelm, MD, Medical Clinic, Department of Cardiology, Düsseldorf University Hospital
Prof. Thomas Meinertz, MD, Former. Director of the Department of Cardiology and Angiology, University Heart Center Hamburg gGmbH
Eva Mühlhofer, MD, Bayer Vital GmbH, Leverkusen
Prof. Ludwig Neyses, Manchester Royal Infirmary, Manchester
Prof. Johannes Oldenburg, MD, Institute of Experimental Haematolgy and Transfusion Medicine and the Haemophilia Center, University Clinic Bonn
W. Dieter Paar, M.D., Director Medical & Scientific Affairs Germany Austria Switzerland SANOFI
Prof. Hans-Hartmut Peter, MD, Clinical Direktor ret., University Medical Center Freiburg, CCI - Centre of Chronic Immunodeficiency
Prof. Sebastian Schellong, MD, Medical Division II, Municipal Hospital Friedrichstadt, Dresden
Prof. Martin Schumacher, Institute of Medical Biometry and Medical Informatics, University of Freiburg
ESAB Meetings, first funding period (2010-2015)
- Kick-Off: October 14-15, 2010
- 1st Meeting: Januar 17, 2011
- 2nd Meeting: June 27, 2011
- 3rd Meeting: January 23-14, 2012
- 4th Meeting: June 18-19, 2012
- 5th Meeting: February 4-5, 2013
- 6th Meeting: June 24-25, 2013
- 7th Meeting: January 20-21, 2014
